Gene Expression Analysis of Autophagy Markers in Primary and Secondary Myelofibrosis

TL;DR

This study analyzed autophagy markers in myelofibrosis patients and found that higher autophagy gene expression may be linked to better outcomes.

Contribution

The study provides new insights into the role of autophagy in primary and secondary myelofibrosis prognosis.

Findings

No significant difference in Beclin-1 and LC3B-II expression between myelofibrosis patients and controls.

Higher LC3B-II expression in primary myelofibrosis was associated with lower DIPSS scores.

Higher Beclin-1 expression correlated with better survival in myelofibrosis patients.

Abstract

Background/Objectives: According to previous research, the process of autophagy in myeloid neoplasms has proven to be ambivalent depending on the type and stage of the disease. The aim of our work was to investigate the mechanism of autophagy in patients with primary and secondary myelofibrosis. Methods: Based on the RT-PCR method, we retrospectively analyzed the expression of Beclin-1 and LC3B-II in bone marrow cells of patients with primary and secondary myelofibrosis (74 participants) compared to the control group which had patients with lymphoma in a localized stage without bone marrow infiltration (11 participants). Results: There was no statistically significant difference in the expression of Beclin-1 and LC3B-II between patients with primary and secondary myelofibrosis and control participants. Among patients with primary myelofibrosis, higher expression of LC3B-II was statistically significantly associated with lower DIPSS. Higher Beclin-1 expression was statistically significantly associated with better patient survival. Conclusions: Our results suggest that the upregulation of autophagy genes may be associated with favorable prognosis and survival of patients with myelofibrosis.

Figures